Amazon looks to disrupt the competitive pharma market

By Catherine Sturman
With the recent acquisition of Whole Foods, it has been reported that Amazon is looking towards the pharma market With pharmaceuticals becoming a multi...

With the recent acquisition of Whole Foods, it has been reported that Amazon is looking towards the pharma market

With pharmaceuticals becoming a multi-million-dollar industry, Amazon is now looking at ways to expand its services further through developing markets. The pharma market is predicted to reach $1.12 trillion by 2022, something which Amazon would be foolhardy to ignore.

 The recent news that the company has recently hired Box Healthcare Vice President and Managing Director Missy Krasner, signifies Amazon’s interest within the healthcare space, and its current investments in cloud products and services to further advance the healthcare industry.

Since May, Amazon has been selling medical products in areas such as Japan, alongside investing in new technologies such as Google Alexa, which will support patients from home. This is in addition to Amazon’s investment in drone technologies, which could drop pharmaceuticals directly to the patient’s home.

The recent acquisition of health food company Whole Foods even sent Walgreens and CVS Health stock prices falling by over three percent.

However, Amazon faces an uphill battle, with strong regulations to overcome within the industry, as well as PBMs and insurers. However, if the company is able to overcome these challenges, it is sure to grow rapidly. A strong distribution network will further see Amazon grow its market reach within ecommerce and create further competition in terms of drug pricing.

Tech companies are increasingly moving into, and undertaking significant investments in health technologies. Whilst Google has been looking at new innovative ways to provide patient-centred healthcare technologies, and even transportation company Uber has been hiring workers to collaborate with healthcare specialists in two new programmes.

 


 

 

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma